Trevi Therapeutics, Inc.

NASDAQ:TRVI

Biotechnology

Healthcare
$13.51 +2.63%

+$0.43 today

Market cap
$1.93B
Beta
1.05
P/E (TTM)
-53.6
EPS (TTM)
-$0.31
52W Low $5.41High $17.10

Volume 2.02M

Average 1.44M

TRVI Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Trevi Therapeutics, Inc.NASDAQ: TRVI

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development growth accelerates

Q3 FY2026 research & development of $19.06M rose 89.0% year over year, ahead of the +37.5% change in trailing-twelve-month research & development. Sequentially, it rose 25.8% from the prior quarter. Over 3 fiscal years it compounded at +19.1% a year.

Context

  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +89.0% holds above the trailing-twelve-month pace of +37.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$19.06M+25.8% QoQ
Last fiscal yearDec 2025
$33.48M-15.0% YoY
LTMSep 2026
$50.35M+37.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+89.0%——
1 year-15.0%——
3-year CAGR+19.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
33.48M USD
Year-over-year change
-15.0%
4-year CAGR
+9.9%

Research & Development vs competitors

How TRVI compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +37.5% is the 4th highest of 9, against a peer median of +18.4%.
  • Over three fiscal years its annual growth of +19.1% compares with a peer median of +21.2%.
TRVI Competitors
Research & Development for TRVI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACADACADIA Pharmaceuticals Inc.LTM Sep 2026$319.46M USD-7.3%-3.1%26.6%
VCREVicore Pharma Holding ABLTM Jun 2026SEK 238.42M SEK+2.0%+16.0%17927.0%
UPBUpstream Bio, Inc.LTM Mar 2026$147.57M USD+91.5%+94.3%4442.3%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$107.93M USD+58.7%+118.3%539.7%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$58.28M USD-31.8%+5.0%83.7%
LQDALiquidia CorporationLTM Jun 2026$55.75M USD+34.8%+26.4%12.4%
TRVITrevi Therapeutics, Inc.LTM Sep 2026$50.35M USD+37.5%+19.1%—
TENXTenax Therapeutics, Inc.LTM Mar 2026$38.53M USD+145.2%+82.5%—
TBPHTheravance Biopharma, Inc.LTM Mar 2026$31.39M USD-21.6%-18.9%28.6%
Peer median (excluding TRVI) —+18.4%+21.2%83.7%

Competitors are the stored peer set for TRVI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development22.98M19.83M23.68M39.38M33.48M
Selling, General & Admin9.49M10.07M10.24M12.15M15.85M
Operating Expenses32.48M29.91M33.92M51.52M49.33M
Depreciation & Amortization50K43K123K147K144K
EBITDA(32.71M)(27.98M)(28.58M)(47.79M)(42.68M)
EBITDA Margin—————
Operating Income(32.48M)(29.91M)(33.92M)(51.52M)(49.33M)
Operating Margin—————
Interest Income10K1.74M4.75M3.6M6.54M
Interest Expense1.2M780K391K4K0
Other Income / Expenses(1.49M)719K4.83M3.58M6.51M
Income Before Tax(33.96M)(29.19M)(29.1M)(47.94M)(42.82M)
Pre-Tax Margin—————
Income Tax Expense(21K)(36K)(32K)(30K)(64K)
Net Income(33.94M)(29.15M)(29.07M)(47.91M)(42.76M)
Net Margin—————
EPS (Basic)(1.49)(0.45)(0.29)(0.47)(0.29)
EPS (Diluted)(1.49)(0.45)(0.29)(0.47)(0.29)
Weighted Avg Shares22.84M64.54M99.03M101.04M145.1M
Weighted Avg Shares (Diluted)22.84M64.54M99.03M101.04M145.1M

Trevi Therapeutics, Inc.

NASDAQ:TRVI

Intrinsic Alpha fair value

Locked

Current Price

$13.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.